Moderator: Axel Ferrazzini

October 30, 2022

Axel is the managing director of 4iP Council since 2017, a European research council working across a broad variety of industries and sectors to promote the role of intellectual property in innovation. He has a strong background in technology research and policy development. In addition to be an elected member of the ETSI Board since 2014, Axel’s career is rooted in research and development and holds more than 20 patents. He has been selected in the 2022 edition of IAM Strategy 300: The World’s Leading IP Strategists.

Axel has an MS in Computer Science from EPITA and an Executive MBA in innovation strategy and entrepreneurship from the ESSEC & Mannheim business schools.

Andrei Iancu – Congressional Testimony: Hearing on the Patent Eligibility Restoration Act (PERA)

October 13, 2025
On October 8th, 2025, Andrei Iancu testified before the Senate Judiciary Committee, Subcommittee on Intellectual Property during the Hearing on the Patent Eligibility Restoration Act (PERA). Iancu, Partner at Sullivan & Cromwell, former Under Secretary of Commerce for IP and Director of the U.S. Patent and Trademark Office (USPTO), and
Read More

How Europe Lost Global Biopharmaceutical R&D Leadership to the United States: Lessons for Today

September 9, 2025
By Anne Prichett Today, the United States leads the world in biopharmaceutical industry research and development (R&D), supporting nearly five million jobs and generating more than $1.65 trillion in economic output. This position of global leadership, however, is relatively recent. Until the late 1980s, Europe–particularly Germany, France,
Read More

If Private Sector R&D Is the Future, IP Policy Must Catch Up

September 8, 2025
By Chris Borges The President’s Budget Request for fiscal year 2026 (FY 2026) includes steep cuts to federal research and development (R&D) funding—a troubling signal for U.S. innovation and economic security. While congressional committees may push back on the most severe reductions, the signs are clear: Federal R&D funding is likely
Read More